DK141773C - - Google Patents

Info

Publication number
DK141773C
DK141773C DK422475A DK422475A DK141773C DK 141773 C DK141773 C DK 141773C DK 422475 A DK422475 A DK 422475A DK 422475 A DK422475 A DK 422475A DK 141773 C DK141773 C DK 141773C
Authority
DK
Denmark
Application number
DK422475A
Other languages
Danish (da)
Other versions
DK141773B (da
DK422475A (enExample
Inventor
D A L Davies
Original Assignee
Searle G.D. & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle G.D. & Co Ltd filed Critical Searle G.D. & Co Ltd
Publication of DK422475A publication Critical patent/DK422475A/da
Publication of DK141773B publication Critical patent/DK141773B/da
Application granted granted Critical
Publication of DK141773C publication Critical patent/DK141773C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Metal Rolling (AREA)
  • Peptides Or Proteins (AREA)
DK422475AA 1974-09-20 1975-09-19 Fremgangsmåde til fremstilling af et antitumormiddel. DK141773B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB4103774 1974-09-20
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Publications (3)

Publication Number Publication Date
DK422475A DK422475A (enExample) 1976-03-21
DK141773B DK141773B (da) 1980-06-16
DK141773C true DK141773C (enExample) 1980-11-03

Family

ID=10417824

Family Applications (1)

Application Number Title Priority Date Filing Date
DK422475AA DK141773B (da) 1974-09-20 1975-09-19 Fremgangsmåde til fremstilling af et antitumormiddel.

Country Status (7)

Country Link
JP (1) JPS5161640A (enExample)
DE (1) DE2541931A1 (enExample)
DK (1) DK141773B (enExample)
FR (1) FR2285145A1 (enExample)
GB (1) GB1509707A (enExample)
NL (1) NL7511089A (enExample)
SE (1) SE7510505L (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation
JPS5665829A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
EP0037388B1 (fr) * 1980-03-31 1984-12-12 Institut International De Pathologie Cellulaire Et Moleculaire Formes pharmaceutiques, leur préparation et les compositions qui les contiennent
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
JPS62228025A (ja) * 1985-12-27 1987-10-06 Teijin Ltd 抗体複合体の製造方法
WO1988007553A1 (fr) * 1987-03-26 1988-10-06 Teijin Limited Procede de preparation d'un complexe d'anticorps
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
JPS5161640A (en) 1976-05-28
GB1509707A (en) 1978-05-04
DE2541931A1 (de) 1976-04-01
FR2285145A1 (fr) 1976-04-16
SE7510505L (sv) 1976-03-22
FR2285145B1 (enExample) 1980-05-30
NL7511089A (nl) 1976-03-23
DK141773B (da) 1980-06-16
DK422475A (enExample) 1976-03-21

Similar Documents

Publication Publication Date Title
AU471463B2 (enExample)
AU495028B2 (enExample)
AU496555B2 (enExample)
AR199134A1 (enExample)
AR199810A1 (enExample)
AU7205174A (enExample)
AU8476175A (enExample)
BG19618A1 (enExample)
BG19673A1 (enExample)
AU479769A (enExample)
AU479870A (enExample)
AU480264A (enExample)
AU480879A (enExample)
AU481044A (enExample)
AU481086A (enExample)
AU481360A (enExample)
AU481606A (enExample)
AU481763A (enExample)
AU481765A (enExample)
AU481825A (enExample)
AU482014A (enExample)
AU490706A (enExample)
BE830156A (enExample)
BE836321A (enExample)
AU479447A (enExample)